Zacks Investment Research lowered shares of OpGen (NASDAQ:OPGN) from a buy rating to a hold rating in a research note released on Wednesday morning.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

Several other research firms also recently weighed in on OPGN. HC Wainwright set a $6.00 price target on shares of OpGen and gave the stock a buy rating in a research note on Thursday, November 1st. ValuEngine raised shares of OpGen from a hold rating to a buy rating in a research note on Tuesday, July 10th.

Shares of NASDAQ:OPGN traded up $0.01 during midday trading on Wednesday, hitting $1.33. The company’s stock had a trading volume of 75,353 shares, compared to its average volume of 173,372. The company has a current ratio of 2.13, a quick ratio of 1.99 and a debt-to-equity ratio of 0.19. The company has a market cap of $8.20 million, a P/E ratio of -0.14 and a beta of 1.94. OpGen has a 12-month low of $1.18 and a 12-month high of $7.60.

A hedge fund recently bought a new stake in OpGen stock. Acadian Asset Management LLC purchased a new position in OpGen Inc (NASDAQ:OPGN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 58,906 shares of the medical research company’s stock, valued at approximately $105,000. Acadian Asset Management LLC owned approximately 0.99% of OpGen at the end of the most recent quarter. Hedge funds and other institutional investors own 11.36% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Featured Story: Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.